Abstract: Background and Objectives: Beta-lactam antibiotics are reported for some of them to be subject to a rapid degradation in infusion solutions and in human blood samples. However, the current data of stability available in blood samples are limited to a few number of beta-lactam antibiotics, and the methodology of the corresponding studies may be discussed. The objective of the present study is to evaluate the stability of 10 beta-lactam antibiotics in human plasma samples.
Methods: Stability of amoxicillin, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, imipenem, meropenem, and piperacillin was evaluated at low and high concentrations at 20°C, 4°C, -20°C, and -80°C for 1, 7, 60, and 90 days, respectively.
Results: Amoxicillin, cefepime, meropenem, and piperacillin were the least stable antibiotics. The maximum durations allowing the stability for all the evaluated beta-lactams at both tested concentrations were estimated at 3 h, 23 h, 10 days, and 35 days at 20°C, 4°C, -20°C, and -80°C, respectively.
Conclusion: We recommend to transport antibiotic plasma samples in ice at 4°C and even at -20°C if these samples come from external hospitals. Ideally, plasma samples should be stored at -80°C if possible; if not, the analysis of the samples should be performed as soon as possible in the limit of 10 days after a storage at -20°C.
(© 2023 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.)
References: Carlier M, Stove V, Wallis SC, et al. Assays for therapeutic drug monitoring of β‐lactam antibiotics: a structured review. Int J Antimicrob Agents. 2015;46(4):367‐375. doi:10.1016/j.ijantimicag.2015.06.016.
Kong KF, Schneper L, Mathee K. Beta‐lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS. 2010;118(1):1‐36. doi:10.1111/j.1600‐0463.2009.02563.x.
Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423‐435. doi:10.1038/nrmicro2333.
Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the β‐lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. 2015;70(12):3178‐3183. doi:10.1093/jac/dkv201.
Parry MF. Toxic and adverse reactions encountered with new beta‐lactam antibiotics. Bull N Y Acad Med. 1984;60:358‐368.
Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta‐lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis. 2005;24(10):649‐653. doi:10.1007/s10096‐005‐0021‐y.
Tune BM, Hsu CY. Mechanisms of beta‐lactam antibiotic nephrotoxicity. Toxicol Lett. 1990;53(1‐2):81‐86. doi:10.1016/0378‐4274(90)90098‐7.
Mahapatra S, Heffner AC. Septic Shock. In: StatPearls [Internet]. Treasure Island. StatPearls Publishing; 2021.
Potel G, Caillon J, Jacqueline C, Navas D, Kergueris MF, Batard E. Dosage des antibiotiques en réanimation: quand et comment demander et interpréter les tests ? Réanimation. 2006;15(3):187‐192. doi:10.1016/j.reaurg.2006.03.011.
COFRAC. Guide Technique d'accréditation de vérification (portée A) /validation (portée B) des méthodes en biologie médicale SH GTA 04, Section santé humaine, révision, 00, avril 2011; 1–46.
Viaene E, Chanteux H, Servais H, Mingeot‐Leclercq M‐P, Tulkens PM. Comparative stability studies of antipseudomonal β‐lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor‐operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46(8):2327‐2332. doi:10.1128/AAC.46.8.2327‐2332.2002.
Mouton J, Vinks A. Continuous infusion of beta‐lactams. Curr Opin Crit Care. 2007;13(5):598‐606. doi:10.1097/MCC.0b013e3282e2a98f.
Esteban MJ, Cantón E, Rius F. Influence of temperature on degradation kinetics of ceftriaxone in diluted and undiluted human serum. Antimicrob Agents Chemother. 1990;34(6):1268‐1270. doi:10.1128/AAC.34.6.1268.
Carlier M, Waele JJD, Verstraete AG, Stove V. Exploration of the pre‐analytical stability of β‐lactam antibiotics in plasma and blood – implications for therapeutic drug monitoring and pharmacokinetic studies. Clin Chem Lab Med. 2015;53(9):e227‐e230. doi:10.1515/cclm‐2014‐0833.
Zander J, Maier B, Zoller M, et al. Effects of biobanking conditions on six antibiotic substances in human serum assessed by a novel evaluation protocol. Clin Chem Lab Med. 2021;10(4):449. doi:10.3390/antibiotics10040449.
Pinder N, Brenner T, Swoboda S, Weigand MA, Hoppe‐Tichy T. Therapeutic drug monitoring of beta‐lactam antibiotics ‐ influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC‐UV. J Pharm Biomed Anal. 2017;143:86‐93. doi:10.1016/j.jpba.2017.05.037.
D'Cunha R, Bach T, Young BA, et al. Quantification of cefepime, meropenem, piperacillin, and tazobactam in human plasma using a sensitive and robust liquid chromatography‐tandem mass spectrometry method, part 2: stability evaluation. Antimicrob Agents Chemother. 2018;62(9):e00861‐e00818. doi:10.1128/AAC.00861‐18.
Mortensen JS, Jensen BP, Zhang M, Doogue M. Preanalytical stability of piperacillin, Tazobactam, Meropenem, and ceftazidime in plasma and whole blood using liquid chromatography‐tandem mass spectrometry. Ther Drug Monit. 2019;41(4):538‐543. doi:10.1097/FTD.0000000000000650.
Charmillon A, Novy E, Agrinier N, et al. The ANTIBIOPERF study: a nationwide cross‐sectional survey about practices for β‐lactam administration and therapeutic drug monitoring among critically ill patients in France. Clin Microbiol Infect. 2016;22(7):625‐631. doi:10.1016/j.cmi.2016.04.019.
El Mahjoub A, Staub C. Stability of benzodiazepines in whole blood samples stored at varying temperatures. J Pharm Biomed Anal. 2000;23(6):1057‐1063. doi:10.1016/s0731‐7085(00)00393‐9.
World Health Organization. Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO; 2002. 2002.
Belouafa S, Habti F, Benhar S, et al. Statistical tools and approaches to validate analytical methods: methodology and practical examples. Int J Metrol Qual Eng. 2017;8:9. doi:10.1051/ijmqe/2016030.
Processing Request
No Comments.